阿达木单抗治疗成人中重度斑块状银屑病18项临床试验的长期综合安全性
基于18项临床试验中3727例接受阿达木单抗治疗的成人银屑病患者,累计暴露5429.7患者年,评估长期安全性。总不良事件发生率为304.6事件/100患者年,严重感染、结核和机会性感染发生率分别为1.8、0.3和0.02事件/100患者年。非黑素瘤皮肤癌和黑素瘤的标准化发病比分别为1.55和3.04,标准化死亡比为0.34;不良事件发生率保持稳定,未发现新的安全性信号。
要点
- 阿达木单抗累计暴露5429.7患者年,总不良事件发生率为304.6事件/100患者年。
- 严重感染、结核和机会性感染发生率分别为1.8、0.3和0.02事件/100患者年。
- 非黑素瘤皮肤癌标准化发病比1.55,黑素瘤标准化发病比3.04,标准化死亡比0.34。
核心结论
- 阿达木单抗治疗银屑病患者的不良事件发生率保持稳定,与既往分析相比未发现新的安全性信号。
研究设计与样本
- 基于18项临床试验的长期安全性分析,纳入接受至少一剂阿达木单抗的成人银屑病患者3727例,累计暴露5429.7患者年。
主要发现
- 总不良事件发生率为304.6事件/100患者年,最常见不良事件为鼻咽炎、上呼吸道感染和头痛,分别为23.7、12.9和7.9事件/100患者年。
- 严重感染、结核和机会性感染发生率分别为1.8、0.3和0.02事件/100患者年。
- 排除非黑素瘤皮肤癌的恶性肿瘤发生率为0.8事件/100患者年,标准化发病比0.86(95%CI 0.58-1.23)。
- 非黑素瘤皮肤癌和黑素瘤发生率分别为0.6和0.2事件/100患者年,标准化发病比分别为1.55(95%CI 1.10-2.13)和3.04(95%CI 1.11-6.62)。
- 标准化死亡比为0.34(95%CI 0.16-0.65)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adalimumab (Humira® , AbbVie Inc., North Chicago, IL, U.S.A.) is a fully human monoclonal antibody specific for tumour necrosis factor-α that is approved to treat adults with moderate-to-severe chronic plaque psoriasis. OBJECTIVES: To assess long-term safety for patients with psoriasis receiving adalimumab in clinical studies. METHODS: Adalimumab safety data from adults with psoriasis who received at least one adalimumab dose in 18 clinical trials were evaluated. Adalimumab was delivered subcutaneously in all treatment regimens. Treatment-emergent adverse events (AEs) were collected from the first dose to 70 days after the last dose or cut-off date (31 December 2015). AE incidence rates were expressed as events per 100 patient-years (E/100 PYs) of adalimumab exposure. Standardized incidence ratios (SIRs) for malignancies and standardized mortality ratios (SMRs) were calculated. RESULTS: Cumulative exposure was 5429·7 PYs in 3727 patients. Overall, there were 16 536 AEs (304·6 E/100 PYs). The most common AEs were nasopharyngitis, upper respiratory infection and headache (23·7, 12·9 and 7·9 E/100 PYs, respectively). Incidence rates for serious infections, tuberculosis and opportunistic infections were 1·8, 0·3 and 0·02 E/100 PYs, respectively. Incidence of malignancy excluding nonmelanoma skin cancer (NMSC) was 0·8 E/100 PYs [SIR 0·86, 95% confidence interval (CI) 0·58-1·23]. Incidences of NMSC and melanoma were 0·6 and 0·2 E/100 PYs, respectively. The SIR was 1·55 (95% CI 1·10-2·13) for NMSC and 3·04 (95% CI 1·11-6·62) for melanoma. The SMR was 0·34 (95% CI 0·16-0·65). CONCLUSIONS: AE rates remained stable in this analysis of patients with psoriasis receiving adalimumab; no new safety signals were identified compared with earlier analyses.
引用
- Leonardi C, Papp K, Strober B, et al. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2018. PMID: 30169904. doi:10.1111/bjd.17084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。